This guidance will fully update the following:
|
Status
|
In progress
|
| Process |
STA Review
|
| ID number |
1013
|
Provisional Schedule
| Expected publication |
19 July 2017 |
Project Team
| Project lead |
Jenna Dilkes |
Email enquiries
Consultees
| Companies sponsors |
Roche Products (trastuzumab emtansine) |
| Others |
Department of Health |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
Breast Cancer Now |
| Professional groups |
Association of Breast Surgery |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
UK Breast Cancer Group |
Commentators
| Comparator companies |
Actavis (vinorelbine) (Confidentiality agreement not signed, not participating) |
| |
GlaxoSmithKline (lapatinib) (Confidentiality agreement not signed, not participating) |
| |
Hospira UK (vinorelbine) (Confidentiality agreement not signed, not participating) |
| |
Medac UK (vinorelbine) (Confidentiality agreement not signed, not participating) |
| |
Pierre Fabre (vinorelbine) (Confidentiality agreement not signed, not participating) |
| |
Roche Products (capecitabine) (Confidentiality agreement not signed, not participating) |
| |
Wockhardt UK (vinorelbine) (Confidentiality agreement not signed, not participating) |
| Evidence review group |
School of Health and Related Research (ScHARR) |
| General commentators |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
15 June 2017 - 06 July 2017
|
Final appraisal determination |
|
09 May 2017
|
Committee meeting: 3
|
|
25 April 2017
|
Following receipt of additional analyses from the company, the CDF rapid reconsideration topic Trastuzumab emtansine for the treatment of locally advanced or metastatic HER2-positive breast cancer after treatment with trastuzumab and a taxane (review of TA371) will be discussed in committee on Tuesday 09 May 2017 |
|
01 February 2017
|
Committee meeting: 2 |
|
20 December 2016 - 20 January 2017
|
Appraisal consultation: 1 |
|
29 November 2016
|
Committee meeting: 1 |
|
12 July 2016
|
Invitation to participate |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance